Source: Annual Congress 2011 - Experimental pulmonary hypertension
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Farkas, D. Farkas, D. Kraskauskas, J. Gauldie, M. Kolb, N. Voelkel (Richmond, United States Of America; Hamilton, Canada). Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis. Eur Respir J 2011; 38: Suppl. 55, 3334

Member's Comments

No comment yet.

Related content which might interest you: Macitentan reduces progression of TGF-ß1-induced pulmonary fibrosis and pulmonary hypertension Source: Eur Respir J, 52 (2) 1701857; 10.1183/13993003.01857-2017 Year: 2018 Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 40: 93-100 Year: 2012 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir Mon 2012; 57: 148-160 Year: 2012 Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Source: Eur Respir J 2005; 26: 586-593 Year: 2005 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome Source: Eur Respir J 2010; 35: 105-111 Year: 2010 The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis. Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Accelerated ageing in idiopathic pulmonary fibrosis and pulmonary hypertension Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017 Year: 2018 Pulmonary hypertension in sickle cell disease Source: Annual Congress 2007 - ACCP1 - Pulmonary hypertension in sickle cell disease Year: 2007 The effect of lung diseases on pulmonary hypertension and the effect of pulmonary hypertension on the lung Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Pulmonary hypertension in chronic lung disease and hypoxia Source: Eur Respir J, 53 (1) 1801914; 10.1183/13993003.01914-2018 Year: 2019 Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Right ventricular dysfunction in pulmonary hypertension with combined pulmonary fibrosis and emphysema syndrome Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Pulmonary hypertension in interstitial lung disease Source: Eur Respir J 2008; 31: 1357-1367 Year: 2008 Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant Source: Eur Respir J 2007; 30: 715-721 Year: 2007